March 13, 2020 / 12:22 PM / in 25 days

BRIEF-Lexicon Pharmaceuticals Announces Additional Data On Telotristat Ethyl's Antiproliferative Effects In Patients

March 13 (Reuters) - Lexicon Pharmaceuticals Inc:

* LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROME

* LEXICON PHARMACEUTICALS - MAJORITY OF PATIENTS EXPERIENCED PROGRESSION-FREE SURVIVAL IN POST-TELOTRISTAT ETHYL PERIOD, WITH MEDIAN PFS OF 23.7 MONTHS

* LEXICON - OBSERVATIONAL STUDY SHOWED USE OF TELOTRISTAT ETHYL WAS ASSOCIATED WITH MEANINGFUL IMPROVEMENTS IN CARCINOID SYNDROME SYMPTOMS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below